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1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia diagnosed in Western
world, with an incidence of 3–6/105 per year, that increase to 12.8/105 at the age of 65 [1-3].
This disease is characterized by an extremely heterogeneous behavior, with the clinical
course varying from patients who never require therapy to patients with a rapid disease
progression and early resistance to treatment. In fact, about 20% of the patients show an ag‐
gressive course and die within few years from diagnosis [3, 4].
Molecular markers, such as cytogenetic alteration [5], immunoglobulin heavy chain (IGH)
and TP53 genes mutational status [6, 7], zeta associated protein 70 (ZAP70) expression [8]
and CD38 expression [9], help to predict outcomes in CLL. However, their presence in the
absence of clinical symptomatology is not a sufficient criterium to initiate therapy. Further,
even in the absence of these factors, resistance to purine-analogue treatment can occur. This
suggests that additional molecular mechanisms, which confer drug refractoriness in poor-
risk CLL, do exist. In this regard, based on next generation sequencing studies, it was recent‐
ly shown that additional genetic events can predict CLL patients outcome, including
NOTCH1, SF3B1, and BIRC3 mutations [10-15].
A major issue in CLL is the identification of the optimal timing and type of first-line treat‐
ment. In the current recommendation of International Workshop on CLL (IWCLL) updated
guidelines for the diagnosis and treatment of CLL the therapy is reserved for advanced,
symptomatic or progressive disease [16]. Numerous studies showed that, either as first-line
therapy or in relapsed/refractory settings, treatment with new agents, such as alemuzumab,
ofatumumab, lenalidomide, and flavoperidole [17-22] or combination of conventional che‐
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motherapy to target immunotherapy lead to a better response in these patients [23-29].
These approaches significantly reduce the tumor load in refractory patients, even if the ulti‐
mate cure of disease has not yet been achieved. Therefore, CLL remains incurable outside
the setting of allogeneic stem cell transplant (allo-SCT). In fact, up to date this is the only
therapeutical approach that can potentially offer a curable solution to this disease [9]. The
indications for SCT in CLL were established by European Bone Marrow Transplant (EBMT)
[30]. Specifically, based on the evidence of efficacy and potential toxicity of SCT in CLL,
these procedure is designated for high-risk CLL patents. These include: a) patients with
TP53 abnormalities, who fail to achieve complete remission (CR) or who progress within 12
months after purine analogues, b) those who relapse within 24 months after having ach‐
ieved a response with purine-analogue-based combination therapy, c) those who relapsed
after prior autologous SCT and d) patients who are fludarabine refractory [31, 32]. It should
be noted that none of these categories requires assessment of biologic risk factors except cy‐
togenetic detection of TP53 deletions. Ongoing prospective clinical studies will determine
the impact of biomarkers such as IGH mutational status and other cytogenetic abnormalities
in identification of patients at sufficiently high risk for allogeneic SCT use at first CR. Several
groups agree that allogeneic transplant early in the disease course is the best strategy for pa‐
tients with high-risk or poor response to initial therapy. For those with durable first remis‐
sions, the timing of transplant is more controversial. The debate in “when to proceed to a more
aggressive treatment approach?” in CLL is in part driven by the presence of new therapeutic
strategies available for these patients. However, it is unknown how these therapies will
change the indications for or the outcome following transplant in CLL. Nevertheless, these
promising results have already started to impact the transplant recommendations in CLL
patients in a similar manner to chronic myeloid leukemia (CML) patients in imatinib era.
In this chapter the Authors, based on their own experience as well as on the most updated
literature, discuss the usage of autologous and allogeneic SCT in the clinical setting of CLL,
also in the light of the novel biological prognostic indicators.
2. Autologous hematopoietic stem cell transplantation
Autologous stem cell transplantation (ASCT) has been extensively investigated as a treat‐
ment option for CLL patients during the last years.
Evidences from clinical and minimal residual disease (MRD) studies have suggested that
ASCT has curative potential in only few patients. Nevertheless, ASCT might be capable of
prolonged disease control even in CLL with poor-risk features.
Autologous transplantation consists in the collection of stem cells from the patient’s marrow or
peripheral blood before high-dose irradiation or chemotherapy and their subsequent reinfu‐
sion to guarantee a new blood production. The main problems with this procedure are the risk
of re-infusion of leukemic cells that could potentially contaminate the stem cell population and
the difficulty in mobilizing progenitor cell in patients who have received multiple previous
treatments [33, 34]; particularly if purine analogs, have been administrated [35]. In addition,
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the outcome of ASCT is strongly correlated with the status of the disease: patients transplant‐
ed in CR have a much better outcome than those transplanted with active disease [36]. There‐
fore, optimal disease control prior to transplantation is mandatory [33, 34, 37].
Other factors that negatively influence the transplantation outcome and correlate with early
relapse are: the interval between the diagnosis and the transplant, the number of prior lines
of therapy, the presence of adverse cytogenetic abnormalities and of unmutated IGH genes
[36, 38]. In addition, the detection of MRD by either polymerase chain reaction (PCR) or
flow cytometry after transplantation anticipates clinical relapse [39, 40].
As mentioned above, different studies have investigated the role of ASCT in patients with
CLL and the results were controversial. A retrospective matched-pair analysis suggested a
survival advantage for ASCT in 66 patients who had undergone a uniform high dose thera‐
py and transplantation over conventional therapy in 291 patients. With an overall median
follow-up time of 70 and 86 months, survival was significantly longer for the patients who
had undergone ASCT compared with conventionally treated patients [41]. However, in
2011, several prospective studies have failed to confirm the survival advantage of ASCT in
advanced CLL patients [42, 43]. Brion et al. [43] published the results of a prospective multi‐
center randomized trial on the benefit of ASCT using a cyclophosphamide/TBI preparative
regimen in advanced clinical-stage untreated CLL compared to conventional treatment. The
conventional treatment was represented by 6 cicles of miniCHOP; for the ASCT cohort the
scheduled therapy consisted of 3 miniCHOP cicles followed by immediate ASCT for pa‐
tients with a very good partial remission (VGPR) or CR. This study highlights the absence of
differences in median overall survival (OS) between the two groups thus denying the supe‐
riority of ASCT over conventional therapy.
The necessity of additional randomized studies to better clarify the role of ASCT in the man‐
agement of patients with CLL was further emphasized by a comparative study conducted
by the EBMT group in which 621 autografted patients were compared to 630 non-autograft‐
ed patients. Patients autografted within 18 months of diagnosis had a better outcome that
those treated with chemotherapy, but this was offset by an inferior outcome of patients au‐
tografted after 18 months [44]. In addition it was found a promising benefit by the T-cell
mediated cytotoxicity via autologous transplantation in the high-risk CLL population.
Interestingly, Porter et al. [45] reported on the management of a chemo-refractory, CLL pa‐
tient with del(17p) treated with autologous T-cells genetically modified to express anti-
CD19; although the long-term disease control and late toxicities are not yet known, the
patient was in remission [45].
Most of the studies published have relatively short follow up and therefore only focus on
treatment related mortality (TRM) early after transplant, but the late consequences, particu‐
larly the development of secondary myelodysplasia and acute myeloid leukaemia (MDS/
AML), deserve some concern [37]. In fact, among 65 patients treated with fludarabine fol‐
lowed by ASCT, 8 developed MDS/ AML [37, 46]. Of note, in most studies, despite a high
initial CR rate, relapse is common, suggesting that autologous transplant is unlikely to be
curative in CLL [37]. However, based on the present literature, although ASCT cannot be
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considered as a standard treatment it should be considered in the context of clinical trials or
as an innovative therapy to prolong survival in selected patients (i.e. those with chemosensi‐
tivity, absence of unfavorable factors, and transplanted early in the course of the disease).
3. Allogeneic hematopoietic stem cell transplantation
In recent years, allogeneic hematopoietic stem cell transplant (allo-SCT) was visibly
emerged as the favorite treatment option for patients with high-risk CLL. In fact, in contrast
with ASCT, allo-SCT can induce durable responses even in patients refractory to therapy
[47-49]. Studies on the outcomes post ASCT failed to show a plateau effect on survival
curves and resulted in a remarkably high incidence of secondary myelodysplastic syn‐
dromes (9% to 12%) [50]. On the contrary, in most series where allo-SCT has been carried
out, a plateau is observed, with 40–60% of the patients remaining alive and free of disease 5–
6 years after transplantation [39, 44, 46, 48, 49, 51-55]. Therefore, allo-SCT become, in the last
two decades, the first treatment approach with curative potential in CLL.
The crucial anti-leukemic principle of allo-SCT in CLL appears to be the graft-versus-leuke‐
mia effect (GVL). The resultant GVL effect derived from alloreactive donor T cells is the key
mechanism responsible for lowering relapse rates after allo-SCT. There is evidence that the
GVL effect plays an essential role in controlling the disease and reverts poor prognostic bio‐
logical variables such as unmutated IGH genes [56, 57]. In addition, one of the most impor‐
tant advantage of allo-SCT includes infusion of tumor-free hematopoietic progenitor and
effector cells from healthy donors. Of note, it is important to exclude the presence in donor
peripheral blood of a monoclonal population immunophenotypically identical to that of pa‐
tients with CLL; in fact it was demonstrated that CLL clones were found in around 12% of
the first-degree relatives of patients with CLL and in up to 3% of the general population [58].
Nevertheless, the use of allo-SCT is limited due to the advanced age of most patients with
CLL and the high mortality associated with the procedure (in the range 24–47%), main caus‐
es for death being graft-vs host disease (GVHD) and infections.
At present, ongoing prospective clinical studies will determine the impact of biomarkers in‐
cluding IGH mutational status and other cytogenetic abnormalities in identification of pa‐
tients with sufficiently high risk to deserve use of allo-SCT in first CR.
4. Myeloablative allogeneic stem cell transplantation
In myeloablative allo-SCT, patients are given extremely high doses of chemotherapy, with
or without radiation, to wipe out, or “ablate,” the marrow. Then they are given an infusion
of donor stem cells to revive blood cell production and immunity.
Several theoretical advantages of myeloablative allo-SCT over ASCT are: a) none tumor con‐
tamination of the stem cell b) GVL effect to eliminate chemotherapy-resistant leukaemia
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cells by immune mechanisms c) better survival curves. In fact, studies from MD Anderson
Cancer Center demonstrate improved outcome after allogeneic compared to ASCT [59] sug‐
gesting that myeloablative allo-SCT can induce durable remission even in patients with re‐
fractory disease. However, the major limitation of using myeloablative allo-SCT is the
increased risk of transplant-associated morbidity and mortality, mostly from organ failure
due to direct toxicity of the preparative regimen and/or development of GVHD [48, 60, 61].
Registry data from the International Bone Marrow Transplant Research (IBMTR) group and
the EBMT group reported a transplant-related mortality (TRM) of 46% with mortality from
GVHD of 20% [60]. These published data showed that approximately two-thirds of allo‐
transplanted CLL patients will succumb either to TRM or to recurrent disease, and approxi‐
mately one-third will be cured of their disease [54, 60].
Active chronic GVHD is principal determinant of long-term morbidity and significantly re‐
duced long-term health status in patients allografted for various hematological malignancies
[62]. Indeed, transplant-related long-term morbidity after allo-SCT for CLL can be signifi‐
cant but is mainly restricted to those patients who have ongoing active chronic GVHD.
However, in the majority of affected patients clinical symptoms of chronic GVHD resolved
over time, allowing discontinuation of systemic therapeutic immunosuppression after a me‐
dian of 25 months [63]. Further, a high graft rejection rates remain a relevant complication in
myeloablative allo-SCT; a possible explanations could be the significant marrow infiltration
in CLL patients at the time of transplantation, inversely correlated with outcome [64], and
the role played by host dendritic cells, which are seriously defective in CLL patients [65].
Another problem is represented by the high infection rates, that correlated with preexisting
immunosuppression. Infections are the cause of about 50% of all CLL-related deaths [62, 66]
primarily in fludarabine and/or alemtuzumab-refractory patients [16, 67]. Moreover in re‐
cent reports the risk of infections has been clearly correlated with presence of GVHD [57, 63,
65, 68] and refractory disease [67, 69]. In addition, it is important to note that patients with
chemosensitive disease have significantly better outcomes than patients with refractory dis‐
ease, suggesting that an earlier application of allo-SCT may further improve transplantation
outcomes [60, 70, 71].
In conclusion, allo-SCT is a therapy with curative potential in CLL and, in contrast to con‐
ventional treatment, with an high potential of providing long-term disease control even in
patients with a very unfavorable biological and clinical risk profile. However, in addition to
the disease risk, it is necessary to consider patient-related risk factors, such as age and co‐
morbidity, when allo-SCT is performed [63].
5. Reduced-intensity conditioning stem cell transplantation
(nonmyeloablative allo-SCT)
Although myeloablative allo-SCT in CLL can result in durable remissions, rates of TRM are
after unacceptably and greatly reduced its application, even in the most refractory and high-
risk individuals.
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Reduced-intensity conditioning (RIC) regimens were introduced as a way to take advantage
of GVL effect, reducing TRM and making transplant more approachable also in older or
younger patients with comorbidities [72, 73]. These reduced regimens, are associated with
improved TRM; in fact, in 2003, the EBMT reported outcomes of 77 CLL patients who re‐
ceived an allo-SCT [74]. The authors described an encouraging TRM rate of 18%, an impres‐
sive overall response rate of 91%, as well as a 69% complete response rate and a 22% partial
response rate, associated with reduction in the ablative intensity of the preparative regimen.
This lower TRM (18%), when compared with that linked to a myeloablative conditioning
(46%), turned out to be extremely promising [74].
On the contrary, there were no significant differences in terms of OS or progression free sur‐
vival (PFS) between these two groups [74]. In fact, although nonmyeloablative transplants
may carry a stronger safety profile, the rate of relapse was higher than that associated with
traditional myeloablative treatment [74]. Interestingly, instead, Sorror et al. have recently
published data indicating that non-myeloablative transplants can provide a lower risk of re‐
lapse [63]. They reported encouraging long-term outcomes in 82 CLL patients who received
RIC allo-SCT. In this study, at a median follow-up of 5 years, TRM, PFS, and OS were 23%,
39%, and 50%, respectively, suggesting a curative potential for RIC allo-SCT in patients with
relapsed CLL, with a more favorable toxicity profile particularly in older patients who
would not have been eligible to receive myeloablative conditioning regimens [63].
In contrast to ASCT where the efficacy relies exclusively on the cytotoxicity administered
with the high-dose regimen, and in agreement to myeloablative allo-SCT, nonmyeloablative
allo-SCT adds the immune-mediated anti-host activities conferred with the graft as a second
fundamental principle of antileukemic efficacy: the GVL effect.
There is no doubt that the main therapeutic principle of allo-SCT in CLL is GVL activity and
this evidence derives from some remarkable observations such as: 1) decreasing relapse inci‐
dence over time even in RIC allo-SCT, in contrast to ASCT or other intensive therapies [56,
60, 63, 70, 71, 75, 76], 2) durable clinical and molecular responses due to antitumor activity
[77], 3) reduced relapse rates in patients with chronic GVHD [78], 4) increased relapse rates
associated with T cell–depleted grafts [79, 80], 5) high efficacy of donor lymphocyte infu‐
sions (DLIs) in the post-transplant relapse [65, 80].
This finging supports alloreactivity as the principal mechanism responsible for GVL.
On the other hand, the most important cause of RIC allo-SCT failure in CLL patients is the
disease relapse. Early relapses are correlated with chemorefractory disease at the time of
transplantation, the most of time due to the unsuccessfulness of RIC regimens in controlling
the disease before the GVL effect. The late relapse, instead, derives from different mecha‐
nism including: CLL clonal evolution, development of tolerance [80], presence of tumor cells
in “GVCLL sanctuary sites”[63] and an insufficient GVL effect to produce a complete dis‐
ease eradication. Interestingly, an high percentage of these late relapses occurred in lymph
nodes without bone marrow or peripheral blood involvement, or even in patients with MRD
negative status [40, 53, 55, 81, 82].
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Quantitative MRD monitoring by RQ-PCR or flowcytometry is an essential tool to establish
the clinical benefit of allo-SCT in CLL; in fact, the absence of detectable MRD, one year after
allo-SCT, was strongly associated with a reduced risk of clinical relapse. In addition, there
are evidences of a powerful correlation between MRD status and GVL activity, while its di‐
rect involvement for guiding GVL-inducing immunomodulation needs further evaluation
[83]. Therefore quantitative MRD monitoring seems to be mandatory to assure safe and ef‐
fective immunotherapy in the context of allo-SCT [83].
The best approach to post transplant immunotherapy in CLL includes monoclonal antibody
(MoAbs). Some of them, although a still short follow-up, show very promising results and
the use of MoAbs in the conditioning or just after transplant, could improve the results of
allo-SCT. Initially, RIC allo-SCT was associated with the use of only fludarabine and cyclo‐
phosphamide. The CLL3X trial from the German CLL Study Group evaluated the long-term
outcome of RIC allo-SCT in patients with poor-risk CLL who received allogeneic transplant
following fludarabine and cyclophosphamide-based conditioning. The 4-year non relapse
mortality (NRM), event-free survival (EFS), and OS were 23%, 42%, and 65%, respectively.
To improve relapse-free survival following transplant and to modulate the impact of
GVHD, MoAbs have been incorporated into transplant regimens [84]. Alemtuzumab, Ritux‐
imab are the most used MoAbs with recognized clinical activity in CLL. Alemtuzumab is a
humanized anti-CD52 IgG1 MoAb with an activity in reducing the incidence of GVHD but,
also, associated with an high risk of death from opportunistic infections [85]. Rituximab (an‐
ti-CD20 MoAb), instead, used in tandem with RIC preparative regimens, can induce re‐
sponse and help in disease control, decreasing the incidence of acute GVHD and
modulating the GVL effect. [59]. However, there is no clear consensus concerning the opti‐
mal conditioning regimen to be used prior to allo-HCT. Using RIC regimens may reduce
toxic deaths, but the success of non-myeloablative allo-SCT is highly dependent on the che‐
mosensitivity of the disease.
6. Conclusion and future directions
Despite much progress in its treatment, CLL continues to be an incurable disease with
standard treatments. SCT cell transplantation has changed the management of CLL patients
with refractory disease or younger patients with aggressive disease. In particular, ASCT has
partially failed in the treatment of advanced CLL: it prolongs survival in selected patients,
but unfortunately do not cure the disease. In addition, secondary MDS/AML is one of major
complication in autografted patients.
Allo-SCT, conversely, may be an acceptable option: myeloablative allo-SCT is an opportuni‐
ty for younger patients with bulky, refractory, or aggressive disease; RIC allo-SCT, instead,
is an emerging curative possibility for older patients with high-risk disease.
Although allo-SCT appears to result in high response rates and eradication of PCR detectable
MRD, the follow up of most clinical trials is too short to assess whether allo-SCT can cure CLL.
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Future approaches in menagment of CLL must take in consideration the balance between in‐
creased morbidity and mortality of SCT in CLL with the potentiality of new therapy in the
setting of the improvements in outcome.
In the absence of any other treatment modalities currently capable of improving outcome in
CLL, SCT should be considered the main option for patients with high-risk, refractory to
standard therapy or with relapsed after prior ASCT.
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